Skip to Content

Ibritumomab Pregnancy and Breastfeeding Warnings

Ibritumomab is also known as: In-111 Zevalin, Y-90 Zevalin, Zevalin

Ibritumomab Pregnancy Warnings

Animal reproductive toxicology studies of this drug have not been conducted. Immunoglobulins are known to cross the placenta. There are no adequate and well-controlled studies in pregnant women. US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Use should be avoided. US FDA pregnancy category: D Risk Summary: -This drug may cause fetal harm when administered to a pregnant woman. -Potential fetal risk should be considered and informed if pregnancy occurs while receiving treatment with this drug. -Encourage use of adequate methods of contraception during and for a minimum of 12 months following treatment.

See references

Ibritumomab Breastfeeding Warnings

A decision should be made to discontinue breast-feeding or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Unknown Excreted into animal milk: Unknown Comment: -The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. In-111 Zevalin (ibritumomab)." IDEC Pharmaceuticals Corporation, San Diego, CA.

References for breastfeeding information

  1. "Product Information. In-111 Zevalin (ibritumomab)." IDEC Pharmaceuticals Corporation, San Diego, CA.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.